Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Valeant Pharmaceuticals International Inc (NYSE:VRX)

20.27
Delayed Data
As of Jun 29
 +0.27 / +1.35%
Today’s Change
18.55
Today|||52-Week Range
263.81
-80.06%
Year-to-Date
How Will Pershing Fare in June? Look at Valeant
Jun 29 / TheStreet.com - Paid Partner Content
The 2 Big Reasons Valeant Pharmaceuticals Intl. Inc., Shares Are Down 80% in 2016
Jun 29 / MotleyFool.com - Paid Partner Content
Valeant Is Cash-Poor, and Even Bausch & Lomb Division May Not Save It
Jun 29 / TheStreet.com - Paid Partner Content
Valeant Pharmaceuticals International (VRX) Leading In Pre-Market Activity
Jun 29 / TheStreet.com - Paid Partner Content
Valeant Needs Cash and 'Crown Jewel' Bausch & Lomb May Be Losing Value
Jun 29 / TheStreet.com - Paid Partner Content
Forget Valeant, Invest in These Attractive Drug Stocks Instead
Jun 28 / Zacks.com - Paid Partner Content
Wells Fargo Says Even Bausch & Lomb Sale May Not Solve Valeant Problems
Jun 29 / TheStreet.com - Paid Partner Content
14 Toxic Must-Sell Investments That Will Be Hit Hardest by Brexit
Jun 28 / TheStreet.com - Paid Partner Content
Valeant Pharmaceuticals (VRX) Stock Slumps, BMO Initiates Coverage
Jun 29 / TheStreet.com - Paid Partner Content
3 Stocks on my Brexit Shopping List
Jun 28 / TheStreet.com - Paid Partner Content

Today’s Trading

Previous close20.00
Today’s open20.30
Day’s range19.64 - 20.50
Volume17,599,930
Average volume (3 months)31,938,735
Market cap$6.8B
Dividend yield--
Data as of 06/29/2016

Growth & Valuation

Earnings growth (last year)-131.25%
Earnings growth (this year)-34.39%
Earnings growth (next 5 years)+9.00%
Revenue growth (last year)+26.42%
P/E ratioNM
Price/Sales3.32
Price/Book1.16

Competitors

 Today’s
change
Today’s
% change
ALKSAlkermes Plc+0.89+2.09%
MNKMallinckrodt Plc+3.67+6.53%
TAROTaro Pharmaceutical ...+4.07+2.89%
IDXXIDEXX Laboratories I...+2.58+2.91%
Data as of 06/29/2016

Financials

Next reporting dateJuly 28, 2016
EPS forecast (this quarter)$1.62
Annual revenue (last year)$10.4B
Annual profit (last year)-$291.7M
Net profit margin-2.79%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
Chairman &
Chief Executive Officer
Joseph C. Papa
Chief Financial Officer, Director &
Senior VP
Robert L. Rosiello
Corporate headquarters
Laval, Quă©bec

Forecasts

Partner Offers

Search for Jobs